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doi:10.1016/j.numecd.2011.05.007Abstract Background and Aim: High leptin (LPT) is associated with high blood pressure (BP),
insulin resistance and systemic inflammation but also excess body weight and adiposity. To
disentangle these multiple relations, we analyzed BP, HOMA and circulating C-reactive protein
concentration (hs-CRP) in white male adults with different LPT levels but similar age, body mass
index (BMI) and body fat distribution. The novel aspect is the different statistical approach used
to investigate the relation between LPT and the other alterations present in obesity.
Methods and Results: 972 Olivetti Heart Study participants were stratified according to the
median LPT distribution (2.97 ng/ml) into low LPT (l-LPT) and high LPT (h-LPT). The two groups
were then carefully matched for age and BMI. We identified two groups of 207 h-LPT and 207 l-
LPT individuals with overlapping age, BMI and waist/hip ratio. The two groups had different BP
(132.9 16.2/85.7 9.0 vs 128.7 18.2/82.8 9.8 mmHg, pZ 0.014 for SBP and pZ 0.002 for
DBP) and prevalence of hypertension (57% vs 43%, p Z 0.027). Upon separate evaluation of
untreated individuals with BMI< 25 or BMI 25, within the latter subgroup h-LPTcompared with
l-LPT participants (nZ 133 each group) had higher BP (pZ 0.0001), HOMA index (pZ 0.013), hs-
CRP (pZ 0.002) and heart rate (pZ 0.008) despite similar age and BMI. By contrast, within the
normal weight subgroup, h-LPT individuals did not differ from l-LPT (nZ 37 each) for any of
these variables.
Conclusions: High LPT is associatedwith higher BP, HR, hs-CRP and HOMA index independently of
BMI and fat distribution but only among overweight individuals.
ª 2011 Elsevier B.V. All rights reserved.39 81 7464301.
F. Galletti).
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Leptin (LPT) is produced by differentiated adipocytes in
white adipose tissue, but also in other organs with a large
contribution of brain and with greater LPT release in obese
than in lean men [1]. Its main and better known physio-
logical effect, mediated by specific structures in the
hypothalamus, is the suppression of the desire for food and
the increment of energy expenditure by a sympathetically
mediated rise of thermogenesis in brown adipose tissue [2].
In addition, leptin exerts a beneficial effect on insulin
sensitivity [3] but also behaves as a proinflammatory
substance [4] together with other molecules produced
within the adipose tissue [5]. Obesity is associated with
elevated plasma LPT levels, the higher the BMI or the waist
circumference the higher the serum LPT level [6]. However,
the main metabolic actions of LPT are largely ineffective in
this disorder, a condition referred to as leptin resistance
and resembling the condition of insulin resistance observed
in the same individuals [2].
We have previously reported that circulating plasma LPT
levels were directly associated with BP values in a cross-
sectional setting [7] and these data are been also confirmed
[8]. In addition were able to predict the risk to develop
arterial hypertension [9] and metabolic syndrome [10] in
a prospective cohort investigation. These findings sup-
ported the hypothesis raised by the results of previous
studies in animal models of a pathogenic role of hyper-
leptinemia and/or leptin resistance in hypertension.
Given the strong relationship of plasma leptin with
excess body weight and adiposity, we decided to disen-
tangle these relations, analyzing BP, HOMA and circulating
C-reactive protein concentration (hs-CRP) in white male
adults with different LPT levels but with overlapping age,
body mass index (BMI) and body fat distribution. The novel
aspect is the different statistical approach used to inves-
tigate the relation between LPT and the other alterations
present in obesity. The opportunity was also taken to
evaluate the associations of plasma LPT levels with known
indicators of insulin resistance (HOMA index) and low grade
systemic inflammation (hs-CRP) in the same setting.MethodsPopulation
Similarly to previous reports by our group [11], we used the
database of the Olivetti Heart Study, an occupational based
investigation of the genetic, nutritional and metabolic
precursors of cardiovascular disease involving the whole
male workforce of the Olivetti factories of Pozzuoli
(Naples) and Marcianise (Caserta). The local Ethics
Committee approved the study protocol and the partici-
pants gave their informed consent to participate. A total of
972 individuals in the age range 25e74 years (51.5  7.2
years), examined in 1994e5, for whom LPT plasma levels
were available, were considered for the present analysis.
The relevant demographic and anthropometric features of
this group were similar to those of the original OHS
population.Examination procedures
Body weight and height were measured on a standard beam
balance scale with an attached ruler. Body weight was
measured to the nearest 0.1 kg and body height was
measured to the nearest 1.0 cm, with subjects wearing
light indoor clothing without shoes. BMI was calculated
according to the standard formula. Overweight was defined
as a BMI  25. The waist circumference was measured at
the umbilicus level with the subject standing erect with
abdomen relaxed, arms at the sides, and feet together; hip
circumference was measured at the point where the
buttocks extended the maximum, when viewed from the
side. Measurements were performed at the nearest 0.1 cm
with a flexible inextensible plastic tape.
Systolic (SBP) and diastolic (DBP; phase V) blood pres-
sure were taken three times 2 min apart with a random zero
sphygmomanometer (Gelman Hawksley Ltd., Sussex, UK)
after the subject had been sitting for at least 10 min. The
average of the second and third reading was recorded. A
subject was classified as hypertensive if his BP was 140
and/or 90 mm Hg or if he was on current antihypertensive
treatment, according to ESH/ISH guidelines. Resting supine
heart rate was measured by standard 12-lead ECG, recor-
ded in all subjects at 25 mm/s and 1 mV/cm calibration.
Biochemical measurements
A fasting venous blood sample was taken in the seated
position between 8:00 AM and 10:00 AM, after the BP
measurements, for determination of serum LPT, adipo-
nectin, serum insulin, glucose and lipids.
The blood specimens were immediately centrifuged and
stored at 70 C until analyzed. Serum LPT was measured
by an enzyme-linked immunosorbent assay (R&D System
GmbH, Wiesbaden-Nordenstadt, Germany). Intra- and
inter-assay coefficients of variation were 3.0% and 5.4%,
respectively [12]. Serum adiponectin was measured by an
enzyme-linked immunosorbent assay (BioVendor Laboratory
Medicine, Inc., Brno, Czech Republic). Intra- and inter-assay
coefficients of variation were 4.2% and 5.1%, respectively.
High-Sensitivity C-Reactive Protein (hs-CRP) was measured
by an immunoturbidimetric method using a Roche Diag-
nostics, Milan, Italy, automated analyzer. Serum glucose
levels were measured with automated methods (Cobas-
Mira, Roche, Italy). Serum insulin was determined by
radioimmunoassay (Insulin Lisophase; Technogenetics,
Milan, Italy). The homeostatic assessment model (HOMA)
index was used to estimate insulin resistance and calculated
as fasting serum insulin (mU/mL)  fasting serum glucose
(mM)/22.5 [13].
Statistical analysis
Statistical analysis was performed using the Statistical
Package for the Social Sciences (SPSS-PC, version 16; SPSS,
Inc., Chicago, IL). The participants were stratified accord-
ing to the median of plasma LPT distribution of whole OHS
population (2.97 ng/ml) into subjects with low (l-LPT) and
subjects with high LPT (h-LPT) levels. Thereafter, the two
groups of subjects underwent a careful one-by-one
Table 2 Logistic regression analysis: Role of LPT on
Hypertension.
Overweight subjects P
Iindependent variable b  SE OR (95% CI)
h-LPT 1.10  0.29 3.01
(1.70e5.34)
0.0001
Normalweight subjects
h-LPT 0.35  0.59 0.70
(0.22e2.24)
0.55
Models adjusted for smoking, physical activity levels, alcohol
intake. h-LPT: High Leptin.
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sion. We thus identified 207 subjects with l-LPT and 207
with h-LPT, who had the same age and BMI. As the distri-
butions of plasma LPT levels deviated significantly from
normality, they were normalized by log transformation;
log-transformed values were used in the analysis, as
appropriate. Analysis of variance (ANOVA) was used to
assess differences between group means. Cross-tabulation
analysis was used to analyze the frequency of a given
condition across different study groups. The general linear
model was adopted to evaluate the interrelations between
selected variables adjusting for confounders. Logistic
regression analysis was carried out to estimate the role of
LPT on hypertension in overweight and normal weight
participants, separately. Results are expressed as means
and standard deviation unless otherwise indicated. Two
sided P values less than 0.05 were considered statistically
significant.Results
The two groups (n Z 207 each) identified by the one-to-
one matching procedure had, by selection, similar age
and BMI but significantly different plasma LPT levels
(Table 1). The high- and low-leptin groups had also similar
body fat distribution (waist/hip: 0.98  0.04 vs
0.98  0.04) but were found to differ with regard to
prevalence of hypertension (l-LPT Z 43%, h-LPT Z 57%;
c2 Z 5.31; p Z 0.027) and BP levels (Table 1). In addition
logistic regression analysis showed that h-LPT was associ-
ated with hypertension, also adjusting for smoking status,
physical activity levels and alcohol intake, but only in
overweigh participants (O.R. [95% CI]: 3.01 [1.70e5.34];
p Z 0.0001) (Table 2).
In the h-LPT compared with the l-LPT group trends were
observed toward higher HR, hs-CRP and HOMA index levels
as well as toward lower plasma adiponectin concentration:
however, none of these difference attained statistical
significance (Table 1).
With respect to the relationship of plasma LPTwith BP we
detected a significant interaction between LPT and BMI,
both in the l-LPT (p Z 0.031) and the h-LPT group
(pZ 0.039). Therefore, we carried out separate evaluationsTable 1 Characteristics of low LPT and high LPT participants m
l-LPT (n Z 207)
Age (years) 51.37  7.44
BMI (kg/m2) 27.09  2.44
LPT (ng/mL) 1.80  0.83
SBP (mm Hg) 128.7  18.2
DBP (mm Hg) 82.8  9.8
ECG-HR (b/min) 61.40  9.73
hs-CRP (mg/L) 1.57  2.13
HOMA index 2.32  1.50
Adiponectin (mg/mL) 4.83  2.53
GFR (mL/min) 88.7  16.2
M  SD; LPT: leptin, SBP: systolic blood pressure, DBP: diastolic blood
rate, l-LPT: Low Leptin, h-LPT: High Leptin.of participants having normal BMI and of those with over-
weight or obesity. To rule out the possible influence of
antihypertensive drug treatment, in this analysis we
excluded subjects on pharmacological therapy. We identi-
fied 133 pairs of h-LPT and l-LPT untreated subjects with
BMI 25 and 37 pairs of subjects with BMI< 25. Tables 2 and
3 report the relevant features of the two subgroups. Within
both subgroups, the average age and BMI of h-LPT and l-LPT
individuals were again exactly comparable. Among over-
weight participants, the difference in plasma LPT concen-
tration was again associated with significant differences in
BP. Further more, significant differences were detected in
hs-CRP, HOMA index and heart rate (Table 3). Conversely,
among normal weight individuals, no difference between h-
LPT and l-LPT participants was detected in any of these
variables (Table 4).
GFR and plasma adiponectin levels of h-LPT and l-LPT
individuals did not differ either in the normal weight or in
the overweight subgroups.Discussion
This is to our knowledge the first case-control study of
individuals with high versus others with low plasma LPT
concentration, derived from an unselected sample of adult
general population and carefully matched for sex, age, body
mass and fat distribution. Its main findings are threefold:
i) for a comparable body mass and adiposity index, highatched for age and BMI.
h-LPT (n Z 207) P
51.82  8.33 0.557
27.09  2.43 0.983
5.97  2.10 0.000
132.9  16.2 0.014
85.7  9.0 0.002
63.02  8.59 0.072
1.94  1.93 0.067
2.59  1.54 0.082
4.58  2.44 0.309
90.8  17.5 0.190
pressure, ECG-HR: heart rate by ECG, GFR: glomerular filtration
Table 3 Characteristics of untreated subjects matched for age and BMI in overweight subjects.
l-LPT (n Z 133) h-LPT (n Z 133) P
Age(years) 50.24  6.51 51.57  8.11 0.141
BMI (kg/m2) 27.69  1.77 27.73  1.87 0.869
LPT (ng/mL) 1.85  0.81 5.84  2.46 0.001
SBP (mm Hg) 124.5  13.9 132.9  15.1 0.001
DBP (mm Hg) 80.8  8.4 85.9  7.8 0.001
ECG-HR (b/min) 60.13  9.32 63.02  8.26 0.008
hs-CRP (mg/L) 1.33  1.42 2.05  2.15 0.002
HOMA index 2.19  1.22 2.64  1.65 0.013
Adiponectin (mg/mL) 4.59  2.16 4.40  2.40 0.499
GFR (mL/min) 91.9  15.6 92.1  15.4 0.940
M  SD; LPT: leptin, SBP: systolic blood pressure, DBP: diastolic blood pressure, ECG-HR: heart rate by ECG, GFR: glomerular filtration
rate, l-LPT: Low Leptin, h-LPT: High Leptin.
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greater prevalence of hypertension; ii) besides blood pres-
sure, also hs-CRP, insulin resistance and heart rate tend to
be elevated in individuals with higher LPT levels but similar
BMI and fat distribution; iii) excess body weight is a condi-
tion necessary for the detection of these multiple associa-
tions. Altogether, these results are in keeping with previous
cross-sectional reports by our group [10] and others [14e18]
of a significant association of plasma LPT concentration with
BP and metabolic syndrome. Particularly impressive in this
respect is the paper by Itoh and co-workers in which LPTwas
correlated with BP also after weight loss, in obese hyper-
tensive women [17]. Finally, cross-sectional results are in
line with our further reports [9,10] that plasma LPT is
a predictor of the development of HPT and metabolic
syndrome.
Leptin and BP
Aside to the epidemiological evidence, the results of
several experimental studies support the contention that
leptin plays a significant role in BP modulation [19e22]. A
number of clinical studies shed light on the possible
mechanisms whereby hyperleptinemia and the attendant
LPT resistance may contribute to development and main-
tenance of hypertension and eventually of cardiovascular
disease [23e25]. Thus, Eikelis et al. demonstrated that inTable 4 Characteristics of untreated subjects matched for age
l-LPT (n Z 37)
Age(years) 51.10  8.72
BMI (kg/m2) 23.93  0.89
LPT (ng/mL) 1.87  0.74
SBP (mm Hg) 127.0  16.5
DBP (mm Hg) 81.9  9.2
ECG-HR (b/min) 62.22  9.42
hs-CRP (mg/L) 1.38  1.99
HOMA index 2.09  1.59
Adiponectin (mg/mL) 4.57  2.42
GFR (mL/min) 80.3  15.3
M  SD; LPT: leptin, SBP: systolic blood pressure, DBP: diastolic blood
rate, l-LPT: Low Leptin, h-LPT: High Leptin.men with various body size, plasma LPT concentration
correlated with the degree of adiposity and with renal
sympathetic nerve activity determined through the renal
spillover of norepinephrine [26]. Alpha-1-receptor blockade
by bunazosin hydrochloride improves insulin resistance and
decreases plasma LPT levels in hypertensive patients with
hyperleptinemia. These findings suggest that excess LPT
causes sympathetic activation in human obesity [27,28].
The small but significant difference in heart rate found in
our study between subjects with different plasma LPT
levels is in accordance with this hypothesis. Central
sympathetic activation by high LPT levels is translated into
increased sympathetic discharge to brown adipose tissue
but also to other organs and, in particular, to the kidney
[29]. The leptin-mediated renal sympathetic stimulation
may be followed by increased sodium and water retention
and by stimulation of renin secretion.
Leptin and CRP
The relationship between plasma leptin and CRP has been
previously reported. Leptin induces CRP expression in vitro in
human primary hepatocytes [30] as well as in human coronary
artery endothelial cells [31]. Accordingly, studies in healthy
humans show a direct independent association between
leptin and plasma CRP concentrations [32]. Leptin adminis-
tration in vivo increases CRP concentration in non-obeseand BMI in normal weight subjects.
h-LPT (n Z 37) P
49.59  9.27 0.474
23.97  0.84 0.884
5.01  3.22 0.001
124.1  17.4 0.458
80.1  9.0 0.399
61.11  8.49 0.597
1.21  0.97 0.644
1.89  0.72 0.500
4.35  1.79 0.659
88.6  23.4 0.07
pressure, ECG-HR: heart rate by ECG, GFR: glomerular filtration
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perhaps as a consequence of leptin resistance. Besides to
raise CRP production, leptin also promotes intimal monocyte
recruitment [35], elicits macrophage foam cell formation
[36] and induces secretion of proinflammatory cytokines [37].
Conversely, a role of CRP in the induction of leptin resistance
has been proposed. CRP was identified as SLIP-1, one of the
circulating factors known to bind plasma leptin and to reduce
its circulating active form [38]. Moreover, the ability of
human CRP to inhibit leptin binding to its receptor and the
ensuing cell signaling process was shown in HEK293 cells and
hypothalamic neurons in vitro [39].
Leptin and insulin sensitivity
Leptin decreases insulin secretion via direct action on
leptin receptors in pancreatic beta-cells [40], enhances
skeletal muscle glucose uptake and oxidation [41] and
suppresses gluconeogenesis [42]. Conversely, insulin and
glucose appear to stimulate leptin secretion by adipocytes
[43]. Taken together, these results suggest that leptin
resistance may favour insulin resistance and diabetes. Our
data confirm previous reports that increased leptin is
associated with hyperinsulinemia and insulin resistance
independently of BMI [3].
Leptin and related variables in overweight and
normal weight subjects
The most intriguing result of our study was the finding of
a significant interaction between plasma LPT and BMI in
their association with BP and the consequent observation
that the statistical association of plasma LPT with BP was
undetectable in the absence of overweight. A similar
pattern was also observed for the relationship of plasma LPT
to hs-CRP, HOMA index and heart rate. This implies that the
relationship between leptin and related variables is
different in the presence or absence of excess body weight.
The explanation(s) of this finding is (are) not at hand.
However, this finding might be related to the parallel
questions of why plasma leptin concentration was increased
in a substantial group of normal weight individuals in our
study population and where the excess LPT was produced in
these subjects. The answer to these questions could help
understand why in these subjects an elevated LPT concen-
tration was not associated with the unfavourable effects
otherwise observed in overweight individuals.
LPT is physiologically expressed in several other cells
besides the adipocyte and one possibility is that the surplus
of LPT production occurring in subjects without excess
adiposity takes place in one or more sites different from the
adipose tissue. According to Eikelis et al., the brain is
a substantial source of circulating leptin in humans but
probably more so in the obese than in the lean subject [1].
Hyperleptinemia is generally expression of leptin resis-
tance, albeit not a very accurate one: thus, for similarly
elevated plasma LPT levels different degrees of LPT resis-
tance may occur, possibly explaining differences in the
pleiotropic effects of the molecule. A different explanation
could be related to GFR. It is well known that high LPT
levels are associated with a impaired renal function [44].Nevertheless this relationship there was not evident in
“normal” renal function [45], as well as for our results
where GFR was not different between l-LPT and h-LPT
groups, also after stratification for overweight and normal
weight participants.
In this respect, a limitation of our study was the lack of
measurement of the Serum Leptin Interacting Proteins
(SLIPs) and of the circulating leptin-receptor, all factors
able to bind circulating LPT and to alter the active free LPT
concentration in the blood.
Another limitation is the recruitment of white male
participants only, so that its results may be generalized
only to a comparable white male population.
Conclusions and perspectives
In conclusion, our study provides the direct demonstration,
in a case-control study of high LPT vs low LPT adult men
carefully matched for age, BMI and body fat distribution,
that elevated plasma LPT is independently associated with
high BP and higher levels of heart rate, hs-CRP and insulin
resistance. Moreover, it showed that these associations can
be observed in overweight and obese subjects but not in
subjects with normal weight. Although the mechanistic
interpretation of our findings is only speculative, these
results support the hypothesis of a pathogenic role of
hyperleptinemia and leptin resistance in the development
of obesity hypertension and, as a consequence, also
strengthen the potential benefits deriving from correction
of overweight and obesity in the prevention of hypertension
and cardiovascular disease.
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